Story perspectives

Study Reveals Tirzepatide's Cost-Effectiveness for Knee Osteoarthritis

9/16/2025

22 5

Summary

Story summary

A Mass General Brigham study evaluates the cost-effectiveness of GLP-1 receptor agonists, semaglutide and tirzepatide, for knee osteoarthritis and obesity.
Using the OApol simulation model, the analysis considers long-term clinical and economic outcomes.
Tirzepatide offers better health benefits at a lower cost than semaglutide.
Bariatric surgery is the most cost-effective option for eligible patients.
The study calls for improved insurance coverage for GLP-1 agents to enhance patient access.

1 of 1

Story summary

A Mass General Brigham study evaluates the cost-effectiveness of GLP-1 receptor agonists, semaglutide and tirzepatide, for knee osteoarthritis and obesity.
Using the OApol simulation model, the analysis considers long-term clinical and economic outcomes.
Tirzepatide offers better health benefits at a lower cost than semaglutide.
Bariatric surgery is the most cost-effective option for eligible patients.
The study calls for improved insurance coverage for GLP-1 agents to enhance patient access.